| 28.61 -0.8 (-2.72%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.83 | 1-year : | 41.85 |
| Resists | First : | 30.68 | Second : | 35.83 |
| Pivot price | 28.91  |
|||
| Supports | First : | 27.78 | Second : | 25.98 |
| MAs | MA(5) : | 29.44 |
MA(20) : | 28.66 |
| MA(100) : | 22.73 |
MA(250) : | 19.98 |
|
| MACD | MACD : | 1 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 74 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 30.68 | Low : | 14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCS ] has closed above bottom band by 34.3%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.89 - 29.08 | 29.08 - 29.2 |
| Low: | 27.29 - 27.51 | 27.51 - 27.67 |
| Close: | 28.31 - 28.64 | 28.64 - 28.88 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Tue, 03 Mar 2026
Oculis (OCS) to Release Quarterly Earnings on Tuesday - MarketBeat
Mon, 02 Mar 2026
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mon, 02 Mar 2026
Earnings To Watch: Oculis Holding AG (OCS) Reports Q4 2025 Resul - GuruFocus
Sat, 28 Feb 2026
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Fri, 27 Feb 2026
Director Arshad Khanani receives vested Oculis RSU award - Stock Titan
Fri, 27 Feb 2026
Oculis Holding AG (OCS) Stock Analysis: A Promising 52.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 4.514e+007 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 316 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.779e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 352.2 % |
| Return on Equity (ttm) | -33.4 % |
| Qtrly Rev. Growth | 791000 % |
| Gross Profit (p.s.) | 83.33 |
| Sales Per Share | -614.6 |
| EBITDA (p.s.) | -3.65133e+008 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.33 |
| Dividend | 0 |
| Forward Dividend | 344000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|